Table 1 Baseline characteristics of the study population

Age (years)

72 ± 9

75 ± 8

< 0.001

Male sex

66.2%

69.4%

0.49

Body mass index (kg/m²)

24.2 ± 3.7

23.1 ± 3.5

0.002

Smoking

25.5%

23.8%

0.71

Hypertension

87.3%

85.0%

0.54

Dyslipidemia

96.2%

88.9%

0.008

Chronic kidney disease

56.1%

56.9%

0.90

eGFR (ml/min/1.73 m²)

60 ± 22

58 ± 22

0.28

Chronic heart failure

17.2%

14.4%

0.44

HFrEF

3.8%

2.9%

0.70

 (missing data)

0.6%

0.6%

> 0.99

LVEF (%)

61 ± 11

62 ± 10

0.34

 (missing data)

12.1%

7.9%

0.11

Atrial fibrillation

10.8%

12.1%

0.75

Coronary artery disease

65.4%

56.0%

0.037

 (missing data)

0.6%

0.0%

0.32

Stroke

14.0%

18.6%

0.20

HbA1c (%)

7.7 ± 1.4

7.2 ± 1.2

< 0.001

 IFCC units (mmol/mol)

61 ± 15

55 ± 13

< 0.001

 (missing data)

3.8%

2.4%

0.47

SGLT2 inhibitor use

–

 Empagliflozin

35.0%

–

 Dapagliflozin

20.4%

–

 Canagliflozin

15.3%

–

 Other SGLT2 inhibitors

29.3%

–

Aspirin use

80.8%

81.7%

0.88

 (missing data)

0.6%

0.1%

0.69

P2Y12 inhibitor use

87.3%

86.6%

0.93

 (missing data)

0.0%

0.3%

> 0.99

Cilostazol use

29.2%

23.0%

0.12

 (missing data)

1.9%

1.0%

0.56

Anticoagulant use

20.0%

17.4%

0.51

 (missing data)

1.3%

0.1%

0.086

Statin use

83.1%

70.3%

0.001

 (missing data)

1.9%

0.7%

0.27

CLTI

25.5%

23.1%

0.58

Ankle-brachial index

0.58 ± 0.24

0.62 ± 0.22

0.051

 (missing data)

1.9%

1.3%

0.84

Vessel diameter (mm)

4.9 ± 1.0

4.8 ± 0.9

0.33

 (missing data)

1.3%

0.4%

0.48

Lesion length (cm)

14.4 ± 9.3

13.8 ± 9.7

0.48

 (missing data)

0.6%

0.0%

0.32

Severe calcification

10.2%

10.3%

> 0.99

 (missing data)

0.0%

0.1%

> 0.99

Chronic total occlusion

33.5%

28.3%

0.22

 (missing data)

1.3%

0.0%

0.017

Drug coated balloon use

0.70

 IN.PACT Admiral

77.1%

78.8%

 Lutonix

22.9%

21.2%